How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,516 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Terazosin

Cooperative Studies Benign Prostatic Hyperplasia Study Group. 533-9 Men with benign prostatic hyperplasia can (...) be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs (...) Ravilla D RD eng Case Reports Letter India Indian J Ophthalmol 0405376 0301-4738 0 Adrenergic alpha-Antagonists 0 Platelet Aggregation Inhibitors 8L5014XET7 Terazosin XM03YJ541D 2007 11. Terazosin activated Pgk1 and Hsp90 to promote stress resistance 25383758 2014 12 18 2015 02 25 2017 02 20 1552-4469 11 1 2015 Jan Nature chemical biology Nat. Chem. Biol. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. 19-25 10.1038/nchembio.1657 Drugs that can protect against organ damage

2018 Trip Latest and Greatest

142. Latanoprost

of a new antiglaucoma drug lathanoprost, a 0.005% xalathane solution, prostaglandin F2 alpha analog, is studied. A single instillation of xalathane (...) Trial Perspektivy primeneniia analoga prostaglandina F2 al'fa latanoprosta v gipotenzivnoĭ terapii glaukomy. Russia (Federation) Vestn Oftalmol 0415216 0042-465X 0 Adrenergic beta-Antagonists 0 Ophthalmic Solutions 0 Parasympathomimetics 0 Prostaglandins F, Synthetic 01MI4Q9DI3 Pilocarpine 6Z5B6HVF6O latanoprost 817W3C6175 Timolol B7IN85G1HY Dinoprost (...) IM Adrenergic beta-Antagonists administration & dosage therapeutic use Chronic Disease Dinoprost analogs & derivatives Drug Therapy, Combination 1998 8. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Latanoprost versus timolol as first choice therapy in patients with ocular hypertension Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA Record Status

2018 Trip Latest and Greatest

143. Nifedipine

beta 2 -adrenergic-receptor agonists and better tolerated compared with beta 2 -adrenergic-receptor (...) agonists and magnesium sulfate in women with preterm labour. The review was generally well conducted, but the authors’ conclusions regarding magnesium sulphate may be too strong given the small number of trials included in the analyses. Authors' objectives To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labour. Searching MEDLINE, EMBASE, LILACS, Web (...) of this study was to compare the effectiveness of nifedipine versus indomethacin 2011 10. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker ( nifedipine ) and an alpha-blocker (tam Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost

2018 Trip Latest and Greatest

144. Quinapril

-adrenergic signal transduction pathway (...) by the development of fulminant hypertension with cardiac hypertrophy. 2. Seven week old heterozygous TG(mREN2)27 rats were treated for 11 weeks with the AT1-receptor antagonist losartan (10 mg kg[-1]), the ACE-inhibitor quinapril (15 mg kg[-1]) and the direct vasodilator hydralazine (30 mg kg[-1]). Untreated TG and normotensive Sprague-Dawley rats (SD) served as controls. 3. TG(mREN2)27-rats were characterized by arterial hypertension (TG 194+/-3.2 mmHg vs SD (...) The purpose of this study is to compare the impact of two blood pressure lowering treatments (high dose quinapril 2006 3. Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study Record Detail Effects of Quinapril 40 mg

2018 Trip Latest and Greatest

145. Doxazosin

participants. (see ) Verified September 2016 by VA Office of Research and Development Sponsor (...) of cocaine dependence; however, both animal and human studies suggest that medications affecting the noradrenergic system can reduce cocaine craving and use. The investigators will study the effect of doxazosin , an alpha-1 adrenergic antagonist, in reducing cocaine use and anxiety symptoms among cocaine-dependent individuals. In addition, the investigators will identify genetic subpopulations (...) of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. To explore the safety and efficacy of the selective 5-serotonin and norepinephrine reuptake inhibitor duloxetine hydrochloride and alpha-adrenergic receptor blocker (alpha-blocker) doxazosin mesylate-controlled tablets in the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS (...) ).In all, 150 patients were

2018 Trip Latest and Greatest

146. ESC/ESH Management of Arterial Hypertension (Full text)

Rosuvastatin LDH Lactate dehydrogenase LDL-C LDL cholesterol LEAD Lower extremity artery disease LIFE Losartan Intervention For Endpoint reduction in hypertension LV Left ventricular LVH Left ventricular hypertrophy MAP Mean arterial pressure MI Myocardial infarction MR Magnetic resonance MRA Mineralocorticoid receptor antagonist MRI Magnetic resonance imaging MUCH Masked uncontrolled hypertension NORDIL Nordic Diltiazem NS Non-significant NT-proBNP N-terminal pro-B natriuretic peptide o.d. Omni die (every

2018 European Society of Cardiology PubMed

147. Management of Cardiovascular Diseases during Pregnancy (Full text)

antagonist MRHD Maximum recommended human dose MRI Magnetic resonance imaging MS Mitral stenosis mWHO Modified World Health Organization NSTE-ACS Non-ST-elevation acute coronary syndrome NSTEMI Non-ST-elevation myocardial infarction NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OAC Oral anticoagulant OHSS Ovarian hyperstimulation syndrome OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary arterial pressure PCI Percutaneous coronary intervention PE (...) fms-like tyrosine kinase 1 STEMI ST-elevation myocardial infarction SVT Supraventricular tachycardia TAPSE Tricuspid annular plane systolic excursion TdP Torsade de pointes TGA Transposition of the great arteries TR Tricuspid regurgitation UFH Unfractionated heparin UPA Ulipristal acetate VKA Vitamin K antagonist VSD Ventricular septal defect VT Ventricular tachycardia VTE Venous thrombo-embolism WCD Wearable cardioverter-defibrillator WPW Wolff–Parkinson–White 1. Preamble Guidelines summarize

2018 European Society of Cardiology PubMed

149. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha-adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5-ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance (...) of renal deterioration if inadequately treated on medication. Long standing BOO from BPH can progress to incomplete bladder emptying, bilateral hydroureteronephrosis, and ultimately acute and/or chronic renal insufficiency. Although transient urethral catheterization with concomitant medical therapy using an alpha adrenergic antagonist can be considered, it is unlikely that the latter will adequately ameliorate the obstructive process to sufficiently prevent further upper urinary tract deterioration

2019 American Urological Association

151. Male Sexual Dysfunction

Hypertens, 2004. 17: 1135. 199. Kloner, R.A., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol, 2004. 172: 1935. 200. McCullough, A.R., et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology, 2002. 60: 28. 201. Forgue, S.T., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 2006. 61: 280. 202. Nichols, D.J (...) with injection therapy: long-term dropout parameters. J Urol, 2000. 163: 467. 251. Buvat, J., et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol, 1998. 159: 116. 252. Mulhall, J.P., et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol, 1997. 158: 1752. 253. Bechara, A., et al. Comparative study of papaverine plus

2019 European Association of Urology

152. Management of Non-neurogenic Male LUTS

-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 2006. 147 Suppl 2: S88. 132. Kortmann, B.B., et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology, 2003. 62: 1. 133. Barendrecht, M.M., et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn, 2008. 27: 226. 134. Djavan, B., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor (...) enlargement: 2-year results from the CombAT study. J Urol, 2008. 179: 616. 140. Roehrborn, C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010. 57: 123. 141. Nickel, J.C., et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract, 2008

2019 European Association of Urology

153. Chronic Pelvic Pain

urinary tract. J Urol, 1998. 159: 2185. 170. Parsons, C.L., et al. Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J Urol, 2000. 164: 1381. 171. Chelimsky, G., et al. Autonomic Testing in Women with Chronic Pelvic Pain. J Urol, 2016. 196: 429. 172. Charrua, A., et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol Urodyn, 2015. 34: 489. 173

2019 European Association of Urology

156. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

are employed to treat LUTS attributed to BPH, including alpha- adrenergic antagonists (alpha-blockers), beta adrenergic agonists, 5-alpha- reductase inhibitors (5- ARIs), anticholinergics, vasopressin analogs, PDE-5 inhibitors, and phytotherapeutics, which can be utilized alone or in combination to take advantage of their different mechanisms of action. Conversely, there exist clinical scenarios when either conservative management , including life style changes (e.g., fluid restriction, avoidance

2019 American Urological Association

157. Urolithiasis

., et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ, 2016. 355: i6112. 106. Guercio, S., et al. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. J Endourol, 2011. 25: 1137. 107. Ramsey, S., et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol, 2010. 24: 185. 108. Lynch, M.F., et (...) , 1994. 152: 1095. 114. Porpiglia, F., et al. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology, 2000. 56: 579. 115. Dellabella, M., et al. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology, 2005. 66: 712. 116. Campschroer, T., et al. Alpha-blockers as medical expulsive therapy

2019 European Association of Urology

159. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

, in patients with glucose intolerance and diabetes. 35 Short-acting beta adrenergic agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) are established treatments to relieve dyspnea and improve airflow obstruction during ECOPD, but the benefits of combining SABAs and SAMAs compared with using SABAs or SAMAs alone are unclear. 36 Long-acting bronchodilators and inhaled corticosteroids have historically only be used in stable COPD, but there is emerging evidence that an increase in dosage (...) Table 13. Comparison of oral mucolytics versus control, additional outcomes 24 Table 14. Comparison of inhaled corticosteroids with or without inhaled short- and long-acting bronchodilators versus placebo, critical outcomes 25 Table 15. Comparison of inhaled corticosteroids with or without inhaled short- and long-acting bronchodilators versus placebo, additional outcomes 25 Table 16. Comparison of inhaled antibiotics versus placebo 26 Table 17. Long-acting muscarinic antagonists versus placebo 26

2019 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>